UK Media Observer
SEE OTHER BRANDS

The best news from the United Kingdom on media and advertising

Japan Reports USD1.6B Worth of COVID-19 Pills Discarded

(MENAFN) Japan's Ministry of Health announced Wednesday that roughly 240 billion yen (equivalent to $1.6 billion) worth of expired COVID-19 oral treatments were discarded in the fiscal year ending March, media reported.

The medications, which could have treated an estimated 2.5 million individuals, were procured during the peak of the pandemic and distributed at no cost to medical facilities nationwide.

A major shift occurred in May 2023 when the government reclassified COVID-19, placing it in the same category as seasonal flu. This policy change transferred financial responsibility for treatment to patients, leading to a steep drop in usage.

Health officials confirmed that the discarded inventory included 1.75 million doses of Pfizer’s antiviral nirmatrelvir and 780,000 doses of Merck’s molnupiravir.

The government had also secured 2 million doses of ensitrelvir, developed by Shionogi & Co. However, approximately 1.77 million of those remain unused. According to the report, they are likely to be scrapped once they expire.

As of March 2024, over 70 million people in Japan had reportedly been infected with COVID-19. The nation recorded around 132,000 related deaths by August of the previous year.

MENAFN16072025000045017169ID1109808372


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service